- Home
- YI vs VNRX Comparison
YI vs VNRX Comparison
Compare YI & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YI
- VNRX
- Stock Information
- Founded
- YI 2010
- VNRX N/A
- Country
- YI China
- VNRX United States
- Employees
- YI N/A
- VNRX N/A
- Industry
- YI Retail-Drug Stores and Proprietary Stores
- VNRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- YI Consumer Staples
- VNRX Health Care
- Exchange
- YI Nasdaq
- VNRX Nasdaq
- Market Cap
- YI 60.7M
- VNRX 68.3M
- IPO Year
- YI N/A
- VNRX N/A
- Fundamental
- Price
- YI $5.71
- VNRX $0.60
- Analyst Decision
- YI
- VNRX Strong Buy
- Analyst Count
- YI 0
- VNRX 4
- Target Price
- YI N/A
- VNRX $3.50
- AVG Volume (30 Days)
- YI 18.5K
- VNRX 191.7K
- Earning Date
- YI 08-28-2025
- VNRX 08-14-2025
- Dividend Yield
- YI N/A
- VNRX N/A
- EPS Growth
- YI N/A
- VNRX N/A
- EPS
- YI N/A
- VNRX N/A
- Revenue
- YI $1,984,717,013.00
- VNRX $1,319,252.00
- Revenue This Year
- YI N/A
- VNRX $274.46
- Revenue Next Year
- YI N/A
- VNRX $212.60
- P/E Ratio
- YI N/A
- VNRX N/A
- Revenue Growth
- YI N/A
- VNRX 35.10
- 52 Week Low
- YI $4.15
- VNRX $0.40
- 52 Week High
- YI $11.90
- VNRX $0.94
- Technical
- Relative Strength Index (RSI)
- YI 30.89
- VNRX 39.24
- Support Level
- YI $5.35
- VNRX $0.64
- Resistance Level
- YI $7.07
- VNRX $0.73
- Average True Range (ATR)
- YI 0.48
- VNRX 0.04
- MACD
- YI -0.13
- VNRX -0.00
- Stochastic Oscillator
- YI 16.75
- VNRX 19.34
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.